Search This Blog

Tuesday, September 15, 2026

GT Biopharma FDA OK on multiple myeloma IND, focuses on cash position

 GT Biopharma gets FDA clearance for investigator-sponsored IND of GTB-5550 in multiple myeloma, reports ~$11M cash funding operations into Q3 2027

https://finviz.com/stock?t=GTBP&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.